Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study

BACKGROUND: We conducted a phase II study of carboplatin plus nab‐paclitaxel for the treatment of small cell lung cancer (SCLC) after the failure of a prior standard chemotherapy containing platinum, etoposide, irinotecan, and amrubicin if indicated. Patients with interstitial pneumonia complication...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Naoya, Arai, Ryo, Soda, Sayo, Inoue, Takashi, Uchida, Nobuhiko, Nakamura, Yusuke, Masawa, Meitetsu, Kushima, Yoshitomo, Okutomi, Hiroaki, Takemasa, Akihiro, Shimizu, Yasuo, Niho, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058313/
https://www.ncbi.nlm.nih.gov/pubmed/35318811
http://dx.doi.org/10.1111/1759-7714.14394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058313/
https://www.ncbi.nlm.nih.gov/pubmed/35318811
http://dx.doi.org/10.1111/1759-7714.14394

Ejemplares similares